The recent approval of selpercatinib, following the results from LIBRETTO-001 (43) for RET-rearranged NSCLC cases, has sparked keen interest in the detailed characterization of clinicopathologic features and response outcomes of this disease. The gene discussed is RET; the disease is non-small cell lung carcinoma.